Caritas Partners Targets Charitable Support to Elizabeth’s Hope and Weill Cornell Children’s Brain Project to Fight Rare and Inoperable Pediatric Brain Cancers

Brain Tumor Researchers to Be Beneficiaries of Philanthropic NYC Broker-Dealer

NEW YORK, June 4, 2014 Caritas Partners today announced the addition of Elizabeth’s Hope as one of its chartable partners. Elizabeth’s Hope provides funding to the Weill Cornell Children’s Brain Tumor Project, which focuses on treating and finding cures for rare and inoperable brain cancers in children and young adults.

“These two organizations are extremely significant to me on both a professional and personal level,” said Richard C. Naso, founder and chief executive officer of Caritas Partners. “Members of my own family have been extremely close to this cause and were friends of Elizabeth Minter, the young woman whose memory inspires Elizabeth’s Hope. It is our sincere desire to forward Elizabeth’s memory and the cutting-edge research of the Children’s Brain Tumor Project through Caritas’ give-back program.”

Charities are a direct benefactor of Caritas’ one-of-a-kind trading model. When a publicly- traded company chooses to execute a buyback order via Caritas and its parent, du Pasquier & Company, Inc., one of Caritas’ charity partners (or another organization of the client’s choosing) will receive 15-50 percent of Caritas’ commissions on the transaction, depending on the commission rate.

With more than $755 billion in buyback transactions having been authorized in 2013 and their continued ubiquity as a financial tool, the potential of Caritas’ model to affect real change in the work of organizations like the Children’s Brain Tumor Project and Elizabeth’s Hope is tangible and powerful.

“It’s amazing what even a few thousand dollars can help us accomplish in terms of research, materials and providing services to patients,” said Dr. Jeffrey Greenfield, director of the Children’s Brain Tumor Project, who treated Elizabeth Minter. “The work I, Dr. Mark Souweidane and our colleagues are doing provides hope to young people stricken with devastating, inoperable brain cancers, as well as their families. We are immensely proud to have the opportunity to take what we do best and channel it toward the betterment of others’ lives.”

Gliomatosis cerebri and DIPG are just two examples of the devastating brain tumors that typically strike children, adolescents, and young adults. Because they are so rare, these inoperable tumors simply do not get the funding or attention that research scientists need to find a cure.

The Weill Cornell Children’s Brain Tumor Project will offer physicians the unprecedented ability to quickly identify a brain tumor’s “fingerprints” at the molecular level. The genomic data allows for personalized tumor therapy and affords new hope to patients — because that information has previously been prohibitively expensive and time-consuming to obtain. The data will be available thanks to a state-of-the-art gene sequencer, which can identify each tumor’s unique genomic profile, along with the laboratory staff and research scientists to interpret the data.

With that individual genetic information in hand, researchers hope to identify alternative delivery methods and drugs that specifically target each young patient’s tumor.

The Children’s Brain Tumor Project and Elizabeth’s Hope will be preferentially recommended to receive a portion of Caritas’ commissions as it partners with small to large cap corporations on buyback orders. Unlike any other broker-dealer on Wall Street, when Caritas executes a buyback or other transaction, a portion of that transaction will be given to charity – every time.


About Caritas Partners

Caritas Partners is the first company of its kind – a Wall Street firm focused on both shareholder value and social value. Operating as the goodwill division of global broker/dealer du Pasquier & Company and led by a seasoned executive trading team, Caritas uses traditional share repurchases as instruments of social change, by donating a portion of the commission to a charity of the client’s choosing. Its distinctive “Buyback to Give Back” program is a new way to be fiscally and socially responsible in the same transaction, maximizing value for the company and the community. Bottom line, Caritas Partners champion capitalism on a mission. For more information on Caritas Partners and its innovative “Buyback to Give Back” program, please visit

About du Pasquier & Co., Inc.

Founded in 1937, du Pasquier & Company has more than 40 employees located in New York and Paris. As a multi-disciplined, cross border financial services boutique, du Pasquier offers a variety of services to professional and high-net-worth clients including: Asset Management; Brokerage and Risk Management; Investment Banking and Capital Placement; and Institutional Private Equity Placement. du Pasquier Asset Management is a SEC-registered investment advisor.

About the Weill Cornell Children’s Brain Tumor Project

The Children’s Brain Tumor Project was founded in 2011 at the Weill Cornell Pediatric Brain and Spine Center. The project owes its inspiration and launch to Elizabeth Minter, whose battle with gliomatosis cerebri — a rare and inoperable brain tumor — inspired her surgeon, Dr. Jeffrey Greenfield, to undertake a groundbreaking research initiative. In starting the Children’s Brain Tumor Project, Dr. Greenfield joined forces with Dr. Mark Souweidane, who had already spent a decade researching and testing alternative therapeutic delivery systems for other inoperable brain cancers, such as DIPG. The Children’s Brain Tumor Project has a single goal: to bring hope to the hundreds of patients and families each year who confront these heartbreaking diagnoses. For more information, please visit

About Elizabeth’s Hope

Elizabeth’s Hope was founded in 2011 by Elizabeth Minter, along with her family and friends, in collaboration with her neurosurgeon, Dr. Jeffrey Greenfield, director of the Weill Cornell Children’s Brain Tumor Project. Elizabeth’s Hope helps fund the Children’s Brain Tumor Project, a research initiative offering neuroscientists the unprecedented ability to identify the unique molecular “fingerprints” of their patients’ brain tumors. Elizabeth’s Hope helps fund genomic sequencing technology to obtain these “fingerprints” and to make them available pro bono for under-served pediatric patients who would otherwise be unable to have access to or afford this novel treatment. For more information, please visit

Media Contacts:

Melissa Connerton | (917) 595-3039 |

Marcus Hardy | (917) 595-3043 |